Amsterdam Molecular Therapeutics (AMT) licensed the use of interleukin-10 (IL-10) under Schering-Plough’s extensive IL-10 patent portfolio for ex vivo gene therapy for gastrointestinal inflammatory diseases. AMT further develops IL-10 ex vivo gene therapy for maintaining remission in Crohn’s disease in collaboration with Academic Medical Center.